{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field bf7b8a7b-1b55-48cd-b380-2d4e52788f60 --><h2>Update</h2><!-- end field bf7b8a7b-1b55-48cd-b380-2d4e52788f60 -->","summary":null,"htmlStringContent":"<!-- begin item 8080fec1-666b-4f3b-b448-a242a14f5a41 --><!-- end item 8080fec1-666b-4f3b-b448-a242a14f5a41 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a7c9da10-9760-5143-bf20-167f1e832103","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"0e7e6169-53bf-5349-a648-fc1e91064d01","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field ce4a36a1-12d2-4da3-a0cc-189c2ad2f71e --><h3>New evidence</h3><!-- end field ce4a36a1-12d2-4da3-a0cc-189c2ad2f71e -->","summary":null,"htmlStringContent":"<!-- begin item 333e4886-d251-46ca-9fce-3eca89ce4b57 --><!-- begin field 187eda39-73ef-479f-88ff-ad3e9c021f64 --><h3>Evidence-based guidelines</h3><!-- end field 187eda39-73ef-479f-88ff-ad3e9c021f64 --><!-- begin field 18cc6250-d82e-42d2-8b76-aa8629532c5f --><ul><li>Labwohl, M. (2018) Psoriasis. Annals of Internal Medicine. <a data-hyperlink-id=\"ba9b5e93-2c61-40e6-b8f4-a93100a3d494\" href=\"http://annals.org/aim\">www.annals.org.uk</a> [<a data-hyperlink-id=\"34435213-1dfb-4003-bcba-a93100a3d59a\" href=\"http://annals.org/aim/article-abstract/2677390/psoriasis\">Free Full-text</a>]</li></ul><!-- end field 18cc6250-d82e-42d2-8b76-aa8629532c5f --><!-- begin field 4e7c1282-72c8-409f-97de-3b30551c9549 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 4e7c1282-72c8-409f-97de-3b30551c9549 --><!-- begin field dca21fce-e2a8-4bd3-9211-d8593137af8c --><p>No new health technology assessments published since 1 October 2017.</p><!-- end field dca21fce-e2a8-4bd3-9211-d8593137af8c --><!-- begin field 5b9ed2c9-2e48-4e45-950e-03ea517bdce2 --><h3>Economic appraisals</h3><!-- end field 5b9ed2c9-2e48-4e45-950e-03ea517bdce2 --><!-- begin field 2dad5515-72a7-4d86-8066-5bef6e7cca26 --><p>No new economic appraisals relevant to England since 1 October 2017.</p><!-- end field 2dad5515-72a7-4d86-8066-5bef6e7cca26 --><!-- begin field 605d6de2-e886-4e64-9159-1ac55221c60b --><h3>Systematic reviews and meta-analyses</h3><!-- end field 605d6de2-e886-4e64-9159-1ac55221c60b --><!-- begin field ff4c798c-5212-4732-8c1e-32cc6e98c7e7 --><ul><li>Leisner, M., Riis, J., and Schwartz, S., et al (2019) <em>Psoriasis and Risk of Mental Disorders in Denmark.</em> JAMA Dermatology. www.jamanetwork.com [<a href=\"https://jamanetwork.com/journals/jamadermatology/article-abstract/2732602\" data-hyperlink-id=\"bfe4f7c3-8295-4ba8-ac3d-aa4e00a1dd45\">Free Full-text</a>]</li></ul><!-- end field ff4c798c-5212-4732-8c1e-32cc6e98c7e7 --><!-- begin field 2cbfe726-3414-45b0-af6d-e0ce7215c0dd --><h3>Primary evidence</h3><!-- end field 2cbfe726-3414-45b0-af6d-e0ce7215c0dd --><!-- begin field fea4f373-716e-4da0-93af-0efabd32fb77 --><ul><li>NIHR (2018) <em>Biological therapies for psoriasis do not increase serious risk of infection.</em> National Institute for Health Research. <a href=\"https://www.nihr.ac.uk/\" data-hyperlink-id=\"f348c46a-9767-40c6-903a-a93100a3f7e6\">www.nihr.ac.uk</a> [<a href=\"https://discover.dc.nihr.ac.uk/portal/article/4000897/biological-therapies-for-psoriasis-do-not-increase-serious-infection-risk\" data-hyperlink-id=\"a38d207f-84e2-45e4-b64b-a93100a3f913\">Free Full-Text</a>]</li></ul><!-- end field fea4f373-716e-4da0-93af-0efabd32fb77 --><!-- end item 333e4886-d251-46ca-9fce-3eca89ce4b57 -->","subChapters":[]},{"id":"d47c4fa3-fb24-5a16-b173-a5cb2e14b555","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field ecc28b20-97d0-40e8-bdb3-d6320cda441c --><h3>New policies</h3><!-- end field ecc28b20-97d0-40e8-bdb3-d6320cda441c -->","summary":null,"htmlStringContent":"<!-- begin item 69adea0b-2101-4561-ab93-1db0ed9845bb --><!-- begin field f421a3c8-e5ee-4975-b3ed-e99bbafbf7c6 --><p>No new national policies or guidelines since 1 October 2017.</p><!-- end field f421a3c8-e5ee-4975-b3ed-e99bbafbf7c6 --><!-- end item 69adea0b-2101-4561-ab93-1db0ed9845bb -->","subChapters":[]},{"id":"a133d563-72cc-583a-9e8c-43592d56c41a","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 07c1c3ef-dc4f-4826-9198-74242ba3c4c4 --><h3>New safety alerts</h3><!-- end field 07c1c3ef-dc4f-4826-9198-74242ba3c4c4 -->","summary":null,"htmlStringContent":"<!-- begin item 5ff659c0-39ea-40e5-8600-ec623c697c34 --><!-- begin field 702ee949-c08e-41a7-9a51-3fe14326776e --><p>No new safety alerts since 1 October 2017.</p><!-- end field 702ee949-c08e-41a7-9a51-3fe14326776e --><!-- end item 5ff659c0-39ea-40e5-8600-ec623c697c34 -->","subChapters":[]},{"id":"9a535aa3-af80-59b2-a23d-4437d09d0551","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 6cd833e6-86d4-4478-bfab-ee5e4da3dd2e --><h3>Changes in product availability</h3><!-- end field 6cd833e6-86d4-4478-bfab-ee5e4da3dd2e -->","summary":null,"htmlStringContent":"<!-- begin item 96364357-6bbe-42b0-8f5c-e8b6576a34c8 --><!-- begin field c2b09992-863c-483d-a623-0a32b1ebc656 --><ul><li>Ilumya™ has now been approved for treatment of moderate-to-severe plaque psoriasis. For more information <a href=\"https://www.biospace.com/article/releases/sun-pharma-announces-u-s-fda-approval-of-ilumya-tildrakizumab-asmn-for-the-treatment-of-moderate-to-severe-plaque-psoriasis/\" data-hyperlink-id=\"e255f44f-5ce3-4c11-bc21-a8fe009649e2\">see here</a>. </li><li>US FDA approves certolizumab pegol for the treatment of moderate-to-severe plaque psoriasis. For more information <a href=\"https://www.biospace.com/article/releases/ucb-announces-the-approval-of-cimzia-certolizumab-pegol-for-moderate-to-severe-plaque-psoriasis-representing-an-important-new-option-for-patients-in-the-u-s-/\" data-hyperlink-id=\"64bb2039-6d44-43db-b66f-a8fe00964a60\">see here</a>. </li><li>Guselkumab is now recommended as an option for plaque psoriasis in adults, in patients with a PASI ≥ 10 & DLQI >10 who have not responded to systemic therapies including ciclosporin, methotrexate and PUVA. For more information <a href=\"https://www.nice.org.uk/guidance/ta521\" data-hyperlink-id=\"bfbf9511-6528-42bc-ab69-a90000a42eec\">see here</a>. </li><li>Metoject (methotrexate) PEN solution for injection in pre-filled pen is now additionally licensed for the treatment of moderate to severe psoriasis in adult patients who are candidates for systemic therapy. For more information <a href=\"https://www.medicines.org.uk/emc/product/5443/smpc\" data-hyperlink-id=\"a4821a0d-294a-48bf-b85c-a91f00b53159\">see here</a>. </li><li>Hulio has comparable quality, safety and efficacy to Humira (reference product). It will be licenced for arthritis (rheumatoid, juvenile idiopathic and psoriatic), axial spondyloarthritis, psoriasis, hidradenitis suppurativa Crohn’s disease, ulcerative colitis and uveitis. See <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004429/WC500252511.pdf\" data-hyperlink-id=\"3d4b646c-48f5-4781-949e-a93400a2c7bc\">here</a> for more information. </li><li>Tildrakizumab, aninjectable IL-23 inhibitor will be licensed for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. See <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004514/WC500252488.pdf\" data-hyperlink-id=\"52440112-9f46-4593-84c6-a93400a4d10d\">here</a> for more information. </li><li>NICE (2019) <em>Certolizumab pegol for treating moderate to severe plaque psoriasis.</em> National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"1422f9e0-02ae-432c-a056-aa3f00d00ade\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/ta574\" data-hyperlink-id=\"a7e42074-d1b3-4c58-a5e4-aa3f00d00afa\">Free Full-text</a>]</li><li>Tildrakizumab is recommended as an option for treating severe plaque psoriasis in adults (PASI and DLQI >10), only if disease has not responded to other systemic treatments, or these options are contraindicated/not tolerated and it is provided under the commercial arrangement. For more information, see <a href=\"https://www.nice.org.uk/guidance/ta575\" data-hyperlink-id=\"2a048c4e-f5d6-48fb-b616-aa3f00d00b0d\">here</a>. </li><li>The SMC accepts certolizumab pegol for moderate-severe plaque psoriasis in adults who are candidates for systemic therapy. It is restricted to patients who have failed to respond to standard systemic therapies/are intolerant to/have a contra-indication to these treatments. For more information, see <a href=\"https://www.scottishmedicines.org.uk/medicines-advice/certolizumab-pegol-cimzia-fullsubmission-smc2132/\" data-hyperlink-id=\"0f516a2f-3bc9-422a-b4a2-aa3f00ea9439\">here</a>. </li><li>NICE has recommended risankizumab as an option for treating severe plaque psoriasis in adults (PASI >10; DLQI >10) if disease has not responded to systemic treatments (ciclosporin, methotrexate and phototherapy), or these are contraindicated/not tolerated. See <a href=\"http://here/\" data-hyperlink-id=\"e8023281-cbc6-454c-b979-aab2008bdcf1\">here</a> for more information.</li><li>CHMP recommended an extension to an existing indication; from treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 12 years and older, to patients 6 years and older. See <a href=\"https://www.ema.europa.eu/en/medicines/human/EPAR/stelara\" data-hyperlink-id=\"673484ca-0b37-4d98-8ef0-ab5000e43ef4\">here</a> for more information. </li><li>European approval of paediatric license extension for secukinumab (Coesentyx) for moderate-to-severe psoriasis. For more information <a href=\"http://www.pharmatimes.com/news/cosentyx_wins_eu_approval_for_first-line_paediatric_psoriasis_1346098\" data-hyperlink-id=\"5cfb324b-b558-401b-9cfe-ac1000b6bd9e\">see here</a>.</li></ul><!-- end field c2b09992-863c-483d-a623-0a32b1ebc656 --><!-- end item 96364357-6bbe-42b0-8f5c-e8b6576a34c8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}